Literature DB >> 29668904

A whole brain longitudinal study in the YAC128 mouse model of Huntington's disease shows distinct trajectories of neurochemical, structural connectivity and volumetric changes.

Lorena I Petrella1,2, João M Castelhano1,2, Mario Ribeiro1,2, José V Sereno1,2, Sónia I Gonçalves1,2,3, Mário N Laço2, Michael R Hayden4, A Cristina Rego2,5, Miguel Castelo-Branco1,2,5.   

Abstract

Huntington's disease (HD) is a neurodegenerative disorder causing cognitive and motor impairments, evolving to death within 15-20 years after symptom onset. We previously established a mouse model with the entire human HD gene containing 128 CAG repeats (YAC128) which accurately recapitulates the natural history of the human disease. Defined time points in this natural history enable the understanding of longitudinal trajectories from the neurochemical and structural points of view using non-invasive high-resolution multi-modal imaging. Accordingly, we designed a longitudinal structural imaging (MRI and DTI) and spectroscopy (1H-MRS) study in YAC128, at 3, 6, 9 and 12 months of age, at 9.4 T. Structural analysis (MRI/DTI), confirmed that the striatum is the earliest affected brain region, but other regions were also identified through connectivity analysis (pre-frontal cortex, hippocampus, globus pallidus and thalamus), suggesting a striking homology with the human disease. Importantly, we found for the first time, a negative correlation between striatal and hippocampal changes only in YAC128. In fact, the striatum showed accelerated volumetric decay in HD, as opposed to the hippocampus. Neurochemical analysis of the HD striatum suggested early neurometabolic alterations in neurotransmission and metabolism, with a significant increase in striatal GABA levels, and specifically anticorrelated levels of N-acetyl aspartate and taurine, suggesting that the later is homeostatically adjusted for neuroprotection, as neural loss, indicated by the former, is progressing. These results provide novel insights into the natural history of HD and prove a valuable role for longitudinal multi-modal panels of structural and metabolite/neurotransmission in the YAC128 model.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29668904     DOI: 10.1093/hmg/ddy119

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  8 in total

1.  A longitudinal multimodal in vivo molecular imaging study of the 3xTg-AD mouse model shows progressive early hippocampal and taurine loss.

Authors:  Samuel Chiquita; Mário Ribeiro; João Castelhano; Francisco Oliveira; José Sereno; Marta Batista; Antero Abrunhosa; Ana C Rodrigues-Neves; Rafael Carecho; Filipa Baptista; Catarina Gomes; Paula I Moreira; António F Ambrósio; Miguel Castelo-Branco
Journal:  Hum Mol Genet       Date:  2019-07-01       Impact factor: 6.150

2.  Temporal Characterization of Behavioral and Hippocampal Dysfunction in the YAC128 Mouse Model of Huntington's Disease.

Authors:  Cristine de Paula Nascimento-Castro; Elisa C Winkelmann-Duarte; Gianni Mancini; Priscilla Gomes Welter; Evelini Plácido; Marcelo Farina; Joana Gil-Mohapel; Ana Lúcia S Rodrigues; Andreza Fabro de Bem; Patricia S Brocardo
Journal:  Biomedicines       Date:  2022-06-17

3.  Longitudinal diffusion tensor magnetic resonance imaging analysis at the cohort level reveals disturbed cortical and callosal microstructure with spared corticospinal tract in the TDP-43 G298S ALS mouse model.

Authors:  Hans-Peter Müller; David Brenner; Francesco Roselli; Diana Wiesner; Alireza Abaei; Martin Gorges; Karin M Danzer; Albert C Ludolph; William Tsao; Philip C Wong; Volker Rasche; Jochen H Weishaupt; Jan Kassubek
Journal:  Transl Neurodegener       Date:  2019-08-30       Impact factor: 8.014

4.  BACHD Mice Recapitulate the Striatal Parvalbuminergic Interneuron Loss Found in Huntington's Disease.

Authors:  Vyshnavi Rallapalle; Annesha C King; Michelle Gray
Journal:  Front Neuroanat       Date:  2021-05-24       Impact factor: 3.856

5.  C57BL/6 Background Attenuates mHTT Toxicity in the Striatum of YAC128 Mice.

Authors:  Michaela K Back; Johanna Kurzawa; Sonia Ruggieri; Jakob von Engelhardt
Journal:  Int J Mol Sci       Date:  2021-11-23       Impact factor: 5.923

6.  Neuroimaging, Urinary, and Plasma Biomarkers of Treatment Response in Huntington's Disease: Preclinical Evidence with the p75NTR Ligand LM11A-31.

Authors:  Danielle A Simmons; Brian D Mills; Robert R Butler Iii; Jason Kuan; Tyne L M McHugh; Carolyn Akers; James Zhou; Wassim Syriani; Maged Grouban; Michael Zeineh; Frank M Longo
Journal:  Neurotherapeutics       Date:  2021-03-30       Impact factor: 7.620

7.  Cerebellar morphometric and spectroscopic biomarkers for Machado-Joseph Disease.

Authors:  Catarina Oliveira Miranda; Rui Jorge Nobre; Miguel Castelo-Branco; Luís Pereira de Almeida; Vitor Hugo Paiva; João Valente Duarte; João Castelhano; Lorena Itatí Petrella; José Sereno; Magda Santana; Sónia Afonso; Cristina Januário
Journal:  Acta Neuropathol Commun       Date:  2022-03-19       Impact factor: 7.801

8.  Antidepressant Effects of Probucol on Early-Symptomatic YAC128 Transgenic Mice for Huntington's Disease.

Authors:  Cristine de Paula Nascimento-Castro; Ana Claudia Wink; Victor Silva da Fônseca; Claudia Daniele Bianco; Elisa C Winkelmann-Duarte; Marcelo Farina; Ana Lúcia S Rodrigues; Joana Gil-Mohapel; Andreza Fabro de Bem; Patricia S Brocardo
Journal:  Neural Plast       Date:  2018-08-14       Impact factor: 3.599

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.